Publications by authors named "Fabio Nota"
Background: Patients that arrive in the emergency department (ED) with COVID-19-like syndromes testing negative at the first RT-PCR represent a clinical challenge because of the lack of evidence about their management available in the literature. Our first aim was to quantify the proportion of patients testing negative at the first RT-PCR performed in our Emergency Department (ED) that were confirmed as having COVID-19 at the end of hospitalization by clinical judgment or by any subsequent microbiological testing. Secondly, we wanted to identify which variables that were available in the first assessment (ED variables) would have been useful in predicting patients, who at the end of the hospital stay were confirmed as having COVID-19 (false-negative at the first RT-PCR).
View Article and Find Full Text PDFArticle Synopsis
- Homozygous familial hypercholesterolemia (HoFH) is a rare and severe condition that is difficult to treat, often requiring both lipid-lowering medications and lipoprotein apheresis (LA) for management.
- A study comparing two groups of HoFH patients treated with lomitapide and LA showed that lomitapide resulted in a greater reduction in LDL-C levels and a possibly lower cardiovascular event rate, despite the fact that treatment goals were not fully met for a large portion of patients in either group.
- The findings suggest that lomitapide may offer better LDL-C control compared to LA, but further research is necessary to determine its impact on overall cardiovascular risk.